Phase 2 study of LX1031 for the treatment of non-constipating irritable bowel syndrome (IBS)
Lexicon Pharmaceuticals announced positive top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS).
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.